Author
Jennifer Clay Cather
Other affiliations: University of Texas at Austin, University of Texas MD Anderson Cancer Center
Bio: Jennifer Clay Cather is an academic researcher from Baylor University Medical Center. The author has contributed to research in topics: Psoriasis & Medicine. The author has an hindex of 22, co-authored 65 publications receiving 2311 citations. Previous affiliations of Jennifer Clay Cather include University of Texas at Austin & University of Texas MD Anderson Cancer Center.
Topics: Psoriasis, Medicine, Placebo, Ixekizumab, Mycosis fungoides
Papers published on a yearly basis
Papers
More filters
Utrecht University1, Queen's University2, Eastern Virginia Medical School3, Oregon Health & Science University4, University of British Columbia5, Australian National University6, University of Melbourne7, Erasmus University Medical Center8, Manchester Academic Health Science Centre9, Hospital Universitario La Paz10, University of Szeged11, Regeneron12
TL;DR: This 1-year, randomised, double-blinded, placebo-controlled, phase 3 study aimed to evaluate the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids versus placebo with topical cortiosteroids in adults with moderate-to-severe atopic dermatitis.
781 citations
TL;DR: These studies show that S aureus containing superantigen enterotoxins are commonly found in patients with CTCL, especially individuals with erythroderma where they could exacerbate and/or perpetuate stimulate chronic T-cell expansion and cutaneous inflammation.
240 citations
TL;DR: Apremilast, given orally at 20 or 30 mg twice daily, seems to be efficacious, safe, and tolerable for patients with moderate to severe plaque psoriasis, and these results support continuing, longer-term studies.
227 citations
TL;DR: The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.
Abstract: Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.
182 citations
TL;DR: This research examines the role of biomarkers in the detection and treatment of cardiovascular disease and their role in the development and use in the management of inflammatory biomarkers.
Abstract: Dr. Friedewald has received honoraria for speaking from Novartis, East Hanover, New Jersey. Dr. Cather has received honoraria for speaking, consulting, and board membership from Amgen; Abbott Laboratories, Abbott Park, Illinois; Astellas, Tokyo, Japan; and Genentech, South San Francisco, California. Dr. Gelfand has received consulting fees from Amgen; Genentech; Pfizer, New York, New York; Celgene, Summit, New Jersey; and Centocor, Horsham, Pennsylvania. Dr. Gelfand is a grants investigator for Amgen, Centocor, and Pfizer. Dr. Gordon has received honoraria for consulting and research grants from Abbott and Centocor and honoraria for consulting from Amgen. Dr. Gibbons has received honoraria for speaking from Merck, Whitehouse Station, New Jersey; and Novartis. Dr. Grundy is a consultant for Merck; Merck/Schering-Plough, Kenilworth, New Jersey; Kos, Abbott Park, Illinois; Pfizer; Eli Lilly, Indianapolis, Indiana; GlaxoSmithKline, Research Triangle Park, North Carolina; Abbott Laboratories; Fournier, Chenove, France; Bristol-Myers Squibb, Plainsboro, New Jersey; Sankyo, Santa Clara, California; AstraZeneca, Wilmington, Delaware; and Sanofi-Aventis, Bridgewater, New Jersey. Dr. Grundy is a research grants investigator for Merck, Abbott, and Kos. Dr. Jarratt is a research grants investigator for Abbott, Amgen, and Genentech. Dr. Krueger has no relevant financial relationships to disclose. Dr. Ridker has received investigator-initiated research grants from the National Heart, Lung, and Blood Institute, Bethesda, Maryland; the National Cancer Institute, Bethesda, Maryland; AstraZeneca; Novartis; Merck; Sanofi-Aventis; the Donald W. Reynolds Foundation, Las Vegas, Nevada; and the Leducq Foundation, Paris, France. Dr. Ridker is a consultant for AstraZeneca; Merck/Schering-Plough; Dade Behring, Deerfield, Illinois; and Isis Pharmaceuticals, Carlsbad, California. Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women’s Hospital, Boston, Massachusetts, that relate to the use of inflammatory biomarkers in the detection and treatment of cardiovascular disease. Dr. Stone is a consultant for Abbott; Merck; Schering-Plough; and Unilever, Rotterdam, The Netherlands (donated to American Heart Association). Dr. Stone has received honoraria for educational activities from Abbott, Merck, Pfizer, and Unilever. Dr. Roberts has received honoraria for speaking from Merck/ScheringPlough, AstraZeneca, and Novartis.
161 citations
Cited by
More filters
TL;DR: The characteristic features of the different primary cutaneous lymphomas and other hematologic neoplasms frequently presenting in the skin are described, and differences with the previous classification schemes are discussed.
3,530 citations
Duke University1, Johns Hopkins University2, University of Florence3, Leiden University4, Stanford University5, University of Vienna6, University of California, San Francisco7, University of Texas Health Science Center at Houston8, University of Barcelona9, University of Wisconsin-Madison10, University of Zurich11, University of Helsinki12, Yale University13, Mayo Clinic14, University of Turin15, Humboldt University of Berlin16, University of Paris17, St Thomas' Hospital18
TL;DR: These revisions are made to incorporate advances related to tumor cell biology and diagnostic techniques as pertains to mycosis fungoides and Sézary syndrome to clarify certain variables that currently impede effective interinstitution and interinvestigator communication and/or the development of standardized clinical trials in MF and SS.
1,167 citations
Washington University in St. Louis1, University of California, Los Angeles2, National Institute for Health Research3, University of Pittsburgh4, University of Kiel5, University of Wisconsin-Madison6, University of British Columbia7, Campbelltown Hospital8, Kindai University9, Regeneron10, Sanofi S.A.11
TL;DR: Patients who received dupilumab had significantly lower rates of severe asthma exacerbation than those who received placebo, as well as better lung function and asthma control.
Abstract: Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and safety in patients with uncontrolled asthma. Methods We randomly assigned 1902 patients 12 years of age or older with uncontrolled asthma in a 2:2:1:1 ratio to receive add-on subcutaneous dupilumab at a dose of 200 or 300 mg every 2 weeks or matched-volume placebos for 52 weeks. The primary end points were the annualized rate of severe asthma exacerbations and the absolute change from baseline to week 12 in the forced expiratory volume in 1 second (FEV1) before bronchodilator use in the overall trial population. Secondary end points included the exacerbation rate and FEV1 in patients with a blood eosinophil count of 300 or more per cubic millimeter. Asthma control and dupilumab safety were also assessed. Results The annualized rate of severe asthma exacerbations was 0.46 (95% confidence interval [CI], 0.39 to 0.53) among ...
1,115 citations
TL;DR: Vorinostat demonstrated activity in heavily pretreated patients with CTCL and the 400 mg daily regimen had the most favorable safety profile and is being further evaluated.
1,048 citations
Tufts University1, Northwestern University2, Wake Forest University3, Icahn School of Medicine at Mount Sinai4, University of California, San Francisco5, University of Pennsylvania6, University of Alabama at Birmingham7, Saint Louis University8, Anacor Pharmaceuticals Inc.9, American Academy of Dermatology10, Baylor University Medical Center11
TL;DR: An overview of psoriasis including its cardinal clinical features, pathogenesis, prognosis, classification, assessment tools used to evaluate psoriatic arthritis, and the approach to treatment is given.
Abstract: Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this second of 5 sections of the guidelines of care for psoriasis, we give an overview of psoriatic arthritis including its cardinal clinical features, pathogenesis, prognosis, classification, assessment tools used to evaluate psoriatic arthritis, and the approach to treatment. Although patients with mild to moderate psoriatic arthritis may be treated with nonsteroidal anti-inflammatory drugs and/or intra-articular steroid injections, the use of disease-modifying antirheumatic drugs, particularly methotrexate, along with the biologic agents, are considered the standard of care in patients with more significant psoriatic arthritis. We will discuss the use of disease-modifying antirheumatic drugs and the biologic therapies in the treatment of patients with moderate to severe psoriatic arthritis.
780 citations